- Home
- SAGE vs BZH Comparison
SAGE vs BZH Comparison
Compare SAGE & BZH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- BZH
- Stock Information
- Founded
- SAGE 2010
- BZH 1985
- Country
- SAGE United States
- BZH United States
- Employees
- SAGE N/A
- BZH N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- BZH Homebuilding
- Sector
- SAGE Health Care
- BZH Consumer Discretionary
- Exchange
- SAGE Nasdaq
- BZH Nasdaq
- Market Cap
- SAGE 571.7M
- BZH 666.1M
- IPO Year
- SAGE 2014
- BZH 1994
- Fundamental
- Price
- SAGE $9.15
- BZH $23.66
- Analyst Decision
- SAGE Hold
- BZH Strong Buy
- Analyst Count
- SAGE 18
- BZH 3
- Target Price
- SAGE $10.06
- BZH $33.00
- AVG Volume (30 Days)
- SAGE 2.8M
- BZH 325.2K
- Earning Date
- SAGE 07-30-2025
- BZH 07-31-2025
- Dividend Yield
- SAGE N/A
- BZH N/A
- EPS Growth
- SAGE N/A
- BZH N/A
- EPS
- SAGE N/A
- BZH 3.10
- Revenue
- SAGE $47,404,000.00
- BZH $2,436,131,000.00
- Revenue This Year
- SAGE $102.21
- BZH N/A
- Revenue Next Year
- SAGE $43.01
- BZH $14.27
- P/E Ratio
- SAGE N/A
- BZH $7.54
- Revenue Growth
- SAGE N/A
- BZH 13.50
- 52 Week Low
- SAGE $4.62
- BZH $17.37
- 52 Week High
- SAGE $13.47
- BZH $38.22
- Technical
- Relative Strength Index (RSI)
- SAGE 71.54
- BZH 63.10
- Support Level
- SAGE $9.04
- BZH $21.88
- Resistance Level
- SAGE $9.30
- BZH $24.30
- Average True Range (ATR)
- SAGE 0.15
- BZH 0.83
- MACD
- SAGE 0.05
- BZH 0.17
- Stochastic Oscillator
- SAGE 91.35
- BZH 79.87
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About BZH Beazer Homes USA Inc.
Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in over 13 states and over 22 metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the leading sources of revenue for the company. Key metro areas include Atlanta, Las Vegas, Los Angeles, Orlando, and Tampa. The company also focuses on land purchasing and development to support future construction efforts as well as mortgage services for its homebuyers.